Nebivolol Milpharm (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Milpharm, is a β1‑selective beta‑blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure and to improve cardiac function in patients with certain forms of heart failure. It is approved for use in the European Union and is commonly prescribed as part of a comprehensive antihypertensive regimen.

GNH USA supplies Nebivolol Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics across multiple continents.

Nebivolol is a β1‑selective beta‑blocker used primarily in cardiovascular disease management. - Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. - Heart failure (NYHA class II‑III): improves left ventricular ejection fraction and reduces hospitalization risk. - Post‑myocardial infarction remodeling: supports favorable cardiac remodeling and lowers the incidence of subsequent cardiovascular events.

Nebivolol may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Headache: mild and transient. - Dizziness: especially on standing. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe bradycardia: symptomatic low heart rate. - Hypotension: marked blood pressure drop with possible syncope. - Bronchospasm: airway constriction in susceptible patients.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate heart rate and blood pressure before initiation. - Asthma/COPD caution: avoid in patients with active bronchospastic disease. - Renal/hepatic impairment: adjust dose or monitor closely in moderate dysfunction. - Concomitant β‑blockers: avoid combining with other β‑blockers to prevent excessive blockade. - Abrupt discontinuation: taper gradually to reduce risk of rebound hypertension. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Nebivolol can interact with other medicines, and the significance of the interaction determines the management approach.

Major Interactions (Avoid): - Combined β‑blockers: additive cardiac depression. - Calcium‑channel blockers verapamil or diltiazem: may cause profound bradycardia and AV block. - Anti‑arrhythmic agents (e.g., amiodarone): increase risk of conduction disturbances.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect. - Diuretics: can lead to excessive blood pressure reduction. - NSAIDs: may attenuate antihypertensive response. - CYP2D6 inhibitors (e.g., fluoxetine): may raise nebivolol plasma levels.